[go: up one dir, main page]

DK1270595T3 - Anti-CCR4-antistof og dets fragment - Google Patents

Anti-CCR4-antistof og dets fragment

Info

Publication number
DK1270595T3
DK1270595T3 DK01908280T DK01908280T DK1270595T3 DK 1270595 T3 DK1270595 T3 DK 1270595T3 DK 01908280 T DK01908280 T DK 01908280T DK 01908280 T DK01908280 T DK 01908280T DK 1270595 T3 DK1270595 T3 DK 1270595T3
Authority
DK
Denmark
Prior art keywords
ccr4
antibody
fragment
antibody fragment
recombinant antibody
Prior art date
Application number
DK01908280T
Other languages
English (en)
Inventor
Kenya Shitara
Nobuo Hanai
Mikiko Sakurada
Akiko Furuya
Kazuyasu Nakamura
Rinpei Niwa
Kenji Shibata
Emi Hosaka
Motoo Yamasaki
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of DK1270595T3 publication Critical patent/DK1270595T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01908280T 2000-03-03 2001-03-02 Anti-CCR4-antistof og dets fragment DK1270595T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000059508 2000-03-03
JP2000401563 2000-12-28
PCT/JP2001/001656 WO2001064754A1 (fr) 2000-03-03 2001-03-02 Anticorps a recombinaison genique et son fragment

Publications (1)

Publication Number Publication Date
DK1270595T3 true DK1270595T3 (da) 2008-11-10

Family

ID=26586785

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01908280T DK1270595T3 (da) 2000-03-03 2001-03-02 Anti-CCR4-antistof og dets fragment

Country Status (15)

Country Link
US (4) US6989145B2 (da)
EP (2) EP1270595B1 (da)
JP (1) JP3926153B2 (da)
KR (1) KR100890873B1 (da)
CN (1) CN100455599C (da)
AT (1) ATE402192T1 (da)
AU (2) AU2001236073B2 (da)
CA (1) CA2401491C (da)
CY (1) CY1108397T1 (da)
DE (1) DE60134962D1 (da)
DK (1) DK1270595T3 (da)
ES (1) ES2309050T3 (da)
PT (1) PT1270595E (da)
SI (1) SI1270595T1 (da)
WO (1) WO2001064754A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
ES2571230T3 (es) * 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
CA2438375C (en) * 2001-03-06 2014-07-15 Kazuhito Fujiyama Plant cell having animal-type sugar chain adding function
PT1390389E (pt) * 2001-04-26 2009-04-03 Biogen Idec Inc Anticorpos que bloqueiam o cripto e as utilizações dos mesmos
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
WO2003018635A1 (en) * 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Human cdr-grafted antibodies and antibody fragments thereof
EP1455833A1 (en) 2001-12-04 2004-09-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Chimeric molecule for the treatment of th2-like cytokine mediated disorders
WO2003072134A1 (fr) * 2002-02-28 2003-09-04 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et therapeutiques pour la pneumonie interstitielle
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
WO2004072646A1 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5)
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
SI1698640T2 (sl) 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
FR2861395B1 (fr) 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
ATE486611T1 (de) 2003-12-04 2010-11-15 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
WO2005053742A1 (ja) * 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
CA2551110C (en) 2003-12-23 2016-01-19 Tanox, Inc. Treatment of cancer with novel anti-il 13 monoclonal antibodies
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
CA2593212A1 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
WO2009001840A1 (ja) * 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. ADCC活性又はCDC活性を有する抗Prominin-1抗体
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
JP5820800B2 (ja) 2010-03-02 2015-11-24 協和発酵キリン株式会社 改変抗体組成物
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
MY188365A (en) 2010-12-16 2021-12-06 Genentech Inc Diagnosis and treatments relating to th2 inhibition
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
JP6310845B2 (ja) 2012-07-06 2018-04-11 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連脊髄症患者の治療方法および治療剤
HRP20211641T1 (hr) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
US10675349B2 (en) * 2014-10-06 2020-06-09 Dana-Farber Cancer Institute, Inc. Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
KR20180025897A (ko) 2015-07-14 2018-03-09 교와 핫꼬 기린 가부시키가이샤 항체와 조합 투여되는 ido 억제제를 포함하는 종양 치료제
WO2017112564A1 (en) 2015-12-22 2017-06-29 3M Innovative Properties Company Stem-well films for sample partitioning
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
WO2018106699A1 (en) * 2016-12-08 2018-06-14 Nantbio, Inc. Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN112135628B (zh) 2018-03-16 2024-11-22 硕腾服务有限责任公司 抗白介素31的肽疫苗
EP3765500A2 (en) 2018-03-16 2021-01-20 Zoetis Services LLC Interleukin-31 monoclonal antibodies for veterinary use
WO2019191563A1 (en) * 2018-03-29 2019-10-03 Remd Biotherapeutics, Inc. Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
EP3883610A4 (en) 2018-11-20 2022-11-02 Cornell University MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19341A (en) * 1858-02-16 Louis beauche
US160015A (en) * 1875-02-23 Improvement in devices for cutting out sheet-metal washers
US187930A (en) * 1877-02-27 Improvement in processes of preserving meat
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
EP0778892A1 (en) 1995-06-07 1997-06-18 Icos Corporation Macrophage derived chemokine and chemokine analogs
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
WO1999024024A2 (en) 1997-11-12 1999-05-20 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
TWI234464B (en) * 1998-06-26 2005-06-21 Chugai Pharmaceutical Co Ltd Medicine constituents for hypercalcemic crisis
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
WO2003018635A1 (en) 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Human cdr-grafted antibodies and antibody fragments thereof
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
ATE486611T1 (de) * 2003-12-04 2010-11-15 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell

Also Published As

Publication number Publication date
US20050187380A1 (en) 2005-08-25
ATE402192T1 (de) 2008-08-15
KR100890873B1 (ko) 2009-03-31
US6989145B2 (en) 2006-01-24
EP1270595A4 (en) 2005-07-27
CY1108397T1 (el) 2014-02-12
CA2401491C (en) 2011-07-05
JP3926153B2 (ja) 2007-06-06
EP1270595B1 (en) 2008-07-23
US20120276090A1 (en) 2012-11-01
US20020098527A1 (en) 2002-07-25
EP1270595A1 (en) 2003-01-02
EP1992644A1 (en) 2008-11-19
WO2001064754A1 (fr) 2001-09-07
US7666418B2 (en) 2010-02-23
DE60134962D1 (de) 2008-09-04
CA2401491A1 (en) 2001-09-07
AU3607301A (en) 2001-09-12
CN100455599C (zh) 2009-01-28
CN1407993A (zh) 2003-04-02
PT1270595E (pt) 2008-09-16
KR20020089377A (ko) 2002-11-29
ES2309050T3 (es) 2008-12-16
US20100221178A1 (en) 2010-09-02
US8632996B2 (en) 2014-01-21
SI1270595T1 (sl) 2008-12-31
AU2001236073B2 (en) 2006-10-19
US8197814B2 (en) 2012-06-12

Similar Documents

Publication Publication Date Title
DK1270595T3 (da) Anti-CCR4-antistof og dets fragment
EP2298811B8 (en) Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
MXPA03000103A (es) Antigenos de streptococcus.
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
DK1854809T3 (da) Nukleinsyre og tilsvarende protein betegnet 158P1D7, der er anvendelig i behandling og påvisning af blærecancer og andre cancere
IL144265A0 (en) Use of antibodies for the vaccination against cancer
WO2001037874A3 (en) Treatment of psoriasis by using an antibody to tnf alpha
CY1107921T1 (el) Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων
DK1313850T3 (da) Nucleinsyre og tilsvarende protein med navnet 85PB3 anvendelige til behandling og påvisning af cancer
ATE537257T1 (de) Mit iga-nephropathie assoziierte dns
ATE329898T1 (de) Kombinationspräparat zur therapie von immunologischen erkrankungen
WO2001079434A3 (fr) Nouveau polypeptide, signal peptidase humaine 10, et polynucleotide codant pour ce polypeptide
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
WO2001075016A3 (fr) Nouveau polypeptide, tyrosinase humaine 16, et polynucleotide codant pour ce polypeptide
WO2001075036A3 (fr) Nouveau polypeptide, immunophiline humaine 14, et polynucleotide codant pour ce polypeptide
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide
WO2001079431A3 (fr) Nouveau polypeptide, proteine humaine d'interaction 15 avec la proteine huntingtine, et polynucleotide codant pour ce polypeptide
WO2001075006A3 (fr) Nouveau polypeptide, chaîne légere de protéine réseau 37, et polynucléotide codant pour ce polypeptide
UA36920A (uk) Спосіб лікування хронічного катарального гінгівіту у дітей
WO2001075049A3 (fr) Nouveau polypeptide, chaine legere de clathrine humaine 11, et polynucleotide codant pour ce polypeptide
WO2001075051A3 (fr) Nouveau polypeptide, proteine humaine 17 stag3 (antigene stromal), et polynucleotide codant pour ce polypeptide
ITPT20020011A0 (it) Sistema ottico per la misura dell'usurae dei parametri geometrici della linea di contatto in ambito ferroviario.
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide